Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms EMBRACE
- Sponsors Amgen
Most Recent Events
- 30 Nov 2023 This trial has been completed in Hungary according to European Clinical Trials Database record.
- 07 Nov 2023 Status changed from active, no longer recruiting to completed.
- 10 Oct 2023 Planned End Date changed from 10 Nov 2023 to 3 Nov 2023.